Cat

Discussion in 'Sunovion' started by anonymous, Feb 12, 2019 at 7:51 AM.

  1. anonymous

    anonymous Guest

    The respiratory team has grown Brovana 1 million dollars and will be significantly under its $315 million forecast for the year. Lonhola is doing $8 million in sales and that has everyone selling it except the Institutional team. Which is doing almost as good in sales with 25 reps selling Novartis hand-me downs. The pipeline has zero respiratory interest or developments after Lonhola, Brovana is flat, and it’s LOE is up in 18 months. Lonhola is going to get it’s ass handed to it now with a superior product to compete against.

    This is looking more like a respiratory franchise sale of Lonhola to smaller company that needs a niched $50-70 million dollar drug. $8 million in sales and most of it is in wholesalers & inventory for a year of work??? That doesn’t pay all of us and a LTC team long-term. Enough to get a smaller company to buy it. Good luck to everyone.
     
  2. anonymous

    anonymous Guest

    Respiratory team is dead meat. They haven't made a dime of profit in 2 years.
     
  3. anonymous

    anonymous Guest

    They are starting new LTC team in three states
     
  4. anonymous

    anonymous Guest

    Yeah that team is a pilot study. They can’t sell this stuff in a outpatient setting, what makes you think they will have success in a penny-pinching LTC environment? They’ve had LTC coverage for a while now. LTC is a grind and our products are a dime a dozen. Generic world over there unless your an antipsychotic. ROI hasn’t been there even with all the resources they’ve dumped into so far.
     
  5. anonymous

    anonymous Guest

    Everyone in the industry knows if you want to improve sales you give Managed Markets a sales force just look at what it did for............?
     
  6. anonymous

    anonymous Guest

    Ltc takes more work and these Specialist have no clue how to sell 9n this market. Look at all training and guidance they have given. Nothing works
     
  7. anonymous

    anonymous Guest

    There isn’t enough training or resources to help sell Lonhola in a LTC generic environment. We can’t sell it in an outpatient setting, LTC is double the grind. Brovana has limited time left, this LTC sales forces makes no sense. Manage Markets have done a great job of making the higher ups believe in this mission. Hints job security for some favorite peeps. Bought some of them some more time. They are great at that.
     



play:inline;">